Nephrocare Health Services Limited — PPTs, 11-08-2026: Investor Presentation

Here's a summary of NephroPlus's performance and strategy:

**Business Performance:**

NephroPlus reported a strong Q1FY27, with revenue climbing 23.7% year-over-year to ₹281.8 Cr. This growth was fueled by a 13.3% rise in treatments and a 13.0% increase in guests served. Revenue per treatment also saw a healthy 9.2% YoY improvement, indicating pricing power. Adjusted EBITDA surged 30.7% YoY to ₹65.1 Cr, with margins expanding 120 basis points to 23.1%, showcasing operational leverage. Adjusted Profit After Tax (PAT) grew an impressive 41.7% YoY to ₹36.8 Cr.

**Growth Drivers or Strategy:**

The company is focused on consolidating its leadership in India through an asset-light model, expanding into micro-markets, and deepening partnerships with public hospitals. Internationally, it aims to scale operations in the Philippines, Uzbekistan, and KSA, leveraging its expertise and exploring new high-growth markets. A key strategic initiative is the launch of the NephroPlus International Dialysis Academy (NIDA) to build a global talent pipeline for nurses.

**Recent Developments:**

NephroPlus achieved a significant milestone of 550 operating clinics globally, including a 50-clinic expansion in the Philippines this quarter. They also launched the NephroPlus Dialysis Index to monitor clinical outcomes at the patient level.

**Key Financial Metrics:**

* Revenue: ₹281.8 Cr (+23.7% YoY)

* Adjusted EBITDA: ₹65.1 Cr (+30.7% YoY)

* Adjusted PAT: ₹36.8 Cr (+41.7% YoY)

* Adjusted EBITDA Margin: 23.1% (up 120 bps YoY)

**Management Commentary / Outlook:**

Management expressed confidence in their ability to grow profitably and efficiently, highlighting the strength of their India model and its replicability in international markets. They are focused on disciplined capital deployment for long-term value creation and are exploring new geographies through strategic acquisitions or partnerships.